<DOC>
	<DOCNO>NCT02904434</DOCNO>
	<brief_summary>Voriconazole good response rate , improve survival less adverse side effect compare drug treatment invasive fungal infection make desirable therapeutic option child . However , dose unpredictable child lead therapeutic failure . This study aim understand physiological difference child adult lead therapeutic failure voriconazole child .</brief_summary>
	<brief_title>Gastrointestinal Implications Voriconazole Exposure</brief_title>
	<detailed_description>Voriconazole clearance child ( 2-12 year old ) 3-fold high bioavailability one half adult value . An important gap knowledge exist explain mechanism result high clearance lower bioavailability voriconazole place child substantial risk sub-therapeutic concentration treatment failure . Preliminary data suggest intestinal first-pass metabolism responsible low bioavailability child , adult . By inhibit intestinal metabolism grapefruit juice , extent effect intestinal first-pass metabolism voriconazole pharmacokinetics determine . Inpatient child Children 's Hospital Philadelphia receive oral voriconazole standard care enrol open label , cross-over clinical trial monitor plasma voriconazole level voriconazole administration without grapefruit juice inhibit intestinal metabolism voriconazole . The propose research elucidate role intestinal metabolism reduce oral bioavailability voriconazole child , incorporate model simulation guide accurate dosing .</detailed_description>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>1 . Children age 217 year old 2 . Receiving oral voriconazole standard care steadystate concentration ( define 72 hour firstdose 72 hour dose change ) 3 . Informed Consent/Assent appropriate 1 . Allergy inability receive slushy solution , prepare use commercially available frozen grapefruit juice concentrate , cherry syrup , Sprite . 2 . Receiving tacrolimus and/or cyclosporine , affect furanocoumarins , study period 3 . Suspected known hepatic dysfunction ( define liver function test measure 3x upper limit normal within past 1 month , measure standard care ) 4 . Receiving renal replacement therapy ( example peritoneal dialysis , hemodialysis , continuous venovenous hemofiltration , continuous venovenous hemodialysis ) 5 . Receiving therapy extracorporeal membrane oxygenation ( ECMO ) 6 . Patients document pancytopenia , diarrhea , mucositis , active infection</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>voriconazole</keyword>
	<keyword>absorption</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>grapefruit juice</keyword>
	<keyword>bioavailability</keyword>
	<keyword>intestinal first-pass metabolism</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>intestinal</keyword>
</DOC>